GSA Capital Partners LLP bought a new position in Cytokinetics, Inc. (NASDAQ:CYTK) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 12,900 shares of the biopharmaceutical company’s stock, valued at approximately $187,000.

A number of other large investors have also modified their holdings of CYTK. Janus Henderson Group PLC purchased a new stake in shares of Cytokinetics during the 2nd quarter valued at about $32,488,000. Vanguard Group Inc. increased its position in shares of Cytokinetics by 59.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after purchasing an additional 1,168,151 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in shares of Cytokinetics during the 3rd quarter valued at about $14,628,000. State Street Corp increased its position in shares of Cytokinetics by 79.6% during the 2nd quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after purchasing an additional 741,909 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Cytokinetics during the 2nd quarter valued at about $5,172,000. 73.61% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 price target on shares of Cytokinetics in a research report on Monday, September 18th. TheStreet lowered shares of Cytokinetics from a “c” rating to a “d” rating in a research report on Friday, October 27th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Cytokinetics in a research report on Wednesday, September 20th. Needham & Company LLC lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and reduced their price target for the company from $22.00 to $12.00 in a research report on Tuesday, November 21st. Finally, JMP Securities reaffirmed an “outperform” rating and set a $13.00 price target (down previously from $17.00) on shares of Cytokinetics in a research report on Tuesday, November 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $17.64.

Cytokinetics, Inc. (CYTK) opened at $8.85 on Friday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics, Inc. has a 52 week low of $7.00 and a 52 week high of $17.20.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.04. The company had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. research analysts predict that Cytokinetics, Inc. will post -2.4 earnings per share for the current fiscal year.

In related news, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.51, for a total transaction of $67,550.00. Following the completion of the transaction, the chief executive officer now directly owns 70,180 shares in the company, valued at approximately $948,131.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 7,321 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $13.39, for a total value of $98,028.19. Following the transaction, the executive vice president now owns 47,540 shares of the company’s stock, valued at $636,560.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,581 shares of company stock valued at $220,703. 7.20% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “GSA Capital Partners LLP Takes Position in Cytokinetics, Inc. (CYTK)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/14/gsa-capital-partners-llp-takes-position-in-cytokinetics-inc-cytk.html.

Cytokinetics Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.